Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
David R. Spigel(Sarah Cannon), Craig H. Reynolds(Florida Cancer Specialists & Research Institute), David Waterhouse(The US Oncology Network), Edward B. Garon(Translational Research in Oncology), Jason C. Chandler(West Cancer Center), Sunil Babu(Fort Wayne Medical Institute), Paul J. Thurmes(Minnesota Oncology), Alexander I. Spira(Virginia Cancer Specialists), Robert M. Jotte(Rocky Mountain Cancer Centers), Jin Zhu(Bristol-Myers Squibb (United States)), Wen Lin(Bristol-Myers Squibb (United States)), George R. Blumenschein(The University of Texas MD Anderson Cancer Center)
Cited by 226
Abstract
Related Papers
No related papers found
Powered by citation graph analysis